DNA Script vs Saluda Medical

Side-by-side comparison of AI visibility scores, market position, and capabilities

Saluda Medical leads in AI visibility (74 vs 52)
DNA Script logo

DNA Script

ChallengerLife Sciences & BioTech

Enzymatic DNA Synthesis Technology

DNA Script has raised $335M total including a $165M oversubscribed Series C; received CE Mark in 2025 for SYNTAX System in clinical labs across Europe; developing enzymatic DNA synthesis printers that enable on-demand, benchtop DNA production for.

AI VisibilityBeta
Overall Score
C52
Category Rank
#69 of 198
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
51
Perplexity
54
Gemini
55

About

DNA Script is a biotechnology company founded in 2014 and headquartered in Paris, France (with US operations in South San Francisco), that has developed a breakthrough enzymatic DNA synthesis (EDS) platform. Traditional chemical-based DNA synthesis — the process of producing custom DNA sequences used in genomics, synthetic biology, diagnostics, and therapeutic development — relies on hazardous chemicals and generates significant toxic waste. DNA Script's approach replaces these chemicals with enzymes (specifically terminal deoxynucleotidyl transferase, or TdT), enabling faster, greener, and more scalable DNA production at the benchtop.

Full profile
Saluda Medical logo

Saluda Medical

LeaderLife Sciences & BioTech

Neuromodulation & Spinal Cord Stimulation

Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.

AI VisibilityBeta
Overall Score
B74
Category Rank
#10 of 198
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
72
Perplexity
68
Gemini
80

About

Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.

Full profile

AI Visibility Head-to-Head

52
Overall Score
74
#69
Category Rank
#10
78
AI Consensus
73
stable
Trend
stable
51
ChatGPT
72
54
Perplexity
68
55
Gemini
80
46
Claude
71
49
Grok
71

Key Details

Category
Enzymatic DNA Synthesis Technology
Neuromodulation & Spinal Cord Stimulation
Tier
Challenger
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.